HÁJEK, Roman, Viera SANDECKÁ, Ivan ŠPIČKA, Marc RAAB, Hartmut GOLDSCHMIDT, Susanne BECK, Jiří MINAŘÍK, Petr PAVLÍČEK, Jakub RADOCHA, Adriana HEINDORFER, Tomáš JELÍNEK, Lukáš STEJSKAL, Lucie BROŽOVÁ, Sabina ŠEVČÍKOVÁ, Jan STRAUB, Tomáš PIKA, Luděk POUR, Vladimír MAISNAR, Anja SECKINGER and Dirk HOSE. Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model. British journal of haematology. Hoboken: Wiley-Blackwell, 2020, vol. 190, No 2, p. 189-197. ISSN 0007-1048. Available from: https://dx.doi.org/10.1111/bjh.16572.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model
Authors HÁJEK, Roman (203 Czech Republic, guarantor), Viera SANDECKÁ (203 Czech Republic), Ivan ŠPIČKA (203 Czech Republic), Marc RAAB (276 Germany), Hartmut GOLDSCHMIDT (276 Germany), Susanne BECK (276 Germany), Jiří MINAŘÍK (203 Czech Republic), Petr PAVLÍČEK (203 Czech Republic), Jakub RADOCHA (203 Czech Republic), Adriana HEINDORFER (203 Czech Republic), Tomáš JELÍNEK (203 Czech Republic), Lukáš STEJSKAL (203 Czech Republic), Lucie BROŽOVÁ (203 Czech Republic, belonging to the institution), Sabina ŠEVČÍKOVÁ (203 Czech Republic, belonging to the institution), Jan STRAUB (203 Czech Republic), Tomáš PIKA (203 Czech Republic), Luděk POUR (203 Czech Republic), Vladimír MAISNAR (203 Czech Republic), Anja SECKINGER (276 Germany) and Dirk HOSE (276 Germany).
Edition British journal of haematology, Hoboken, Wiley-Blackwell, 2020, 0007-1048.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 6.998
RIV identification code RIV/00216224:14110/20:00116111
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1111/bjh.16572
UT WoS 000549486800038
Keywords in English multiple myeloma; prognostic marker; risk factors; overall survival; progression-free survival
Tags 14110518, 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 3/8/2020 13:15.
Abstract
Smouldering multiple myeloma (SMM) presents without MM defining symptoms. We aimed to identify patients with SMM with an 80% risk of progression within 2 years using only serum parameters. In total, 527 patients with SMM were included and divided into a training group (287 patients from the Czech Myeloma Group [CMG]) and an independent validation group (240 patients from Heidelberg). The median follow-up was 2 center dot 4 and 2 center dot 5 years, respectively. Progression to MM occurred in 51 center dot 9% of the CMG and 38 center dot 8% of the Heidelberg patients, respectively. The median risk of progression was 11 center dot 0% (CMG) and 9 center dot 7% (Heidelberg) per year, during the 5 years after diagnosis. A serum involved/uninvolved free light-chain ratio of >30, immunoparesis, and serum monoclonal (M) protein of >= 2 center dot 3 g/dl emerged as powerful predictors of 2-year progression rate with a hazard ratio (HR) of 2 center dot 49 (95% confidence interval [CI] 1 center dot 49-4 center dot 17), HR of 2 center dot 01 (95% CI 1 center dot 36-2 center dot 96) and HR of 2 center dot 00 (95% CI 1 center dot 44-2 center dot 79) (P < 0 center dot 001) in univariate Cox regression analysis, respectively. Based on this, the CMG model identified patients with SMM with a 2-year risk of progression of 78 center dot 7% (95% CI 53 center dot 1-95 center dot 7; HR 6 center dot 8;P < 0 center dot 001, CMG) and 81 center dot 3% (95% CI 47 center dot 1-98 center dot 8; HR 38 center dot 63;P < 0 center dot 001, Heidelberg). Serum parameters in the CMG model allow identification of patients with SMM with an 80% risk of progression to symptomatic MM within 2 years.
PrintDisplayed: 13/7/2024 17:23